MATRONE, ANTONIO
 Distribuzione geografica
Continente #
NA - Nord America 4.617
EU - Europa 3.237
AS - Asia 1.606
AF - Africa 252
SA - Sud America 107
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 3
Totale 9.832
Nazione #
US - Stati Uniti d'America 4.522
IT - Italia 967
CN - Cina 781
DE - Germania 772
SE - Svezia 545
SG - Singapore 405
AT - Austria 225
GB - Regno Unito 220
BG - Bulgaria 218
CI - Costa d'Avorio 163
RU - Federazione Russa 117
IN - India 94
TR - Turchia 83
BR - Brasile 82
VN - Vietnam 80
CA - Canada 78
SN - Senegal 72
HK - Hong Kong 68
FI - Finlandia 33
CZ - Repubblica Ceca 22
JP - Giappone 21
NL - Olanda 18
PL - Polonia 15
FR - Francia 13
GR - Grecia 13
IR - Iran 13
UA - Ucraina 13
KR - Corea 11
AU - Australia 10
ID - Indonesia 8
MX - Messico 8
BE - Belgio 7
CL - Cile 7
IE - Irlanda 7
CR - Costa Rica 6
PK - Pakistan 6
AZ - Azerbaigian 5
CH - Svizzera 5
ES - Italia 5
MG - Madagascar 5
AR - Argentina 4
EC - Ecuador 4
EG - Egitto 4
HU - Ungheria 4
IQ - Iraq 4
LT - Lituania 4
PH - Filippine 4
UZ - Uzbekistan 4
CY - Cipro 3
IL - Israele 3
SK - Slovacchia (Repubblica Slovacca) 3
TW - Taiwan 3
VE - Venezuela 3
ZA - Sudafrica 3
BH - Bahrain 2
CO - Colombia 2
DK - Danimarca 2
EU - Europa 2
LV - Lettonia 2
MA - Marocco 2
NG - Nigeria 2
RS - Serbia 2
SV - El Salvador 2
UY - Uruguay 2
A1 - Anonimo 1
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
BO - Bolivia 1
BY - Bielorussia 1
EE - Estonia 1
GE - Georgia 1
GT - Guatemala 1
LB - Libano 1
LK - Sri Lanka 1
MT - Malta 1
MY - Malesia 1
OM - Oman 1
PE - Perù 1
PT - Portogallo 1
PY - Paraguay 1
RO - Romania 1
SA - Arabia Saudita 1
TN - Tunisia 1
Totale 9.832
Città #
Chandler 569
Santa Clara 506
Fairfield 411
Shanghai 303
Ashburn 298
Milan 262
Houston 235
Woodbridge 223
Sofia 216
Singapore 210
Vienna 210
New York 193
Seattle 171
Abidjan 163
Wilmington 147
Cambridge 132
Princeton 127
Ann Arbor 126
Boardman 126
Beijing 118
Florence 105
Pisa 105
Lawrence 95
Boulder 82
Dakar 72
Serra 71
Frankfurt am Main 68
Medford 66
London 65
Ottawa 58
Hong Kong 56
Istanbul 50
Munich 49
Rome 45
Dong Ket 42
Des Moines 39
Bremen 35
Redwood City 35
Dearborn 33
San Diego 31
Fuzhou 30
Redmond 28
Nanjing 26
Washington 22
Quanzhou 21
Brno 18
Ogden 18
Guangzhou 17
Los Angeles 17
Vicopisano 16
Izmir 15
Cascina 14
Helsinki 14
Lancaster 14
Nuremberg 14
Bengaluru 13
Hyderabad 13
Jiaxing 13
Hangzhou 12
Lucca 12
Scandicci 12
Norwalk 11
Chengdu 10
Chiesina Uzzanese 10
Changsha 9
Shenyang 9
Tianjin 9
Toronto 9
Hefei 8
Livorno 8
Nanchang 8
Tokyo 8
Wuhan 8
Zhengzhou 8
Brussels 7
Dallas 7
Dublin 7
Genoa 7
Xiamen 7
Boston 6
Hebei 6
Jinan 6
Kunming 6
Montreal 6
Naples 6
Phoenix 6
Pontedera 6
San José 6
São Paulo 6
Antananarivo 5
Buffalo 5
Lappeenranta 5
Mumbai 5
Ningbo 5
Salt Lake City 5
Samsun 5
Santiago 5
Ulan-ude 5
Amsterdam 4
Bari 4
Totale 6.570
Nome #
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 200
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 174
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 172
Targeted Therapy in Thyroid Cancer: State of the Art 168
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 161
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 160
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 159
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 158
A patient with MEN1 and end‑stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation 150
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 150
null 146
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 146
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 144
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 137
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 136
Il carcinoma tiroideo: nuove prospettive terapeutiche. 132
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 130
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 128
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 128
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 127
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 126
Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer 126
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 124
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 124
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 122
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 117
The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy 117
Central Neck Dissection Cannot Be Avoided In Medullary Thyroid Cancer (MTC) On The Basis Of Presurgical Serum Calcitonin (CT) 115
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 114
Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib 112
Potential impact of BMI on the aggressiveness of presentation and clinical outcome of Differentiated Thyroid Cancer 111
null 107
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 107
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 105
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 104
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 103
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 100
Recombinant Human Thyrotropin Stimulation Thyroglobulin (rhTSH-Tg) test can identify false serum tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients 99
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 98
Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience 97
MON-524 Prospective Evaluation of Patients with Encapsulated Classical Variant of Papillary Thyroid Cancer and Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Have They A Similar Prognosis? 97
Increased Risk of Renal Complications in Patients with Chronic Postsurgical Hypoparathyroidism Treated with Conventional Therapy 96
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 95
SAT-393 Cognitive Function Evaluation in an Italian Cohort of Patients with Post-Operative Hypoparathyroidism 95
The Thymic Hyperplasia (TH) And Biochemical Persistence Of Disease In Patients With Differentiated Thyroid Carcinoma (DTC) 95
Cabozantinib: An orphan drug for thyroid cancer 94
Decreased serum vascular endothelial growth factor-D levels in metastatic patients with differentiated thyroid carcinoma 94
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 93
Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism 93
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 93
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 92
After 20 Years, RET genetic screening still identifies new germline and somatic mutations 87
Expression of duox1 in papillary thyroid cancer and in normal thyroid tissues and correlation with ret/ptc rearrangements 87
Risk factors for renal calcifications and determinants of hypercalciuria in patients with chronic, post-surgical hypoparathyroidism 87
null 86
Predictive Value Of High Sensitive Thyroglobulin Assay (USTG) And Neck Ultrasonography (US) At The Time Of Remnant Ablation On Lt-4 Therapy In Patients With Low And Intermediate Risk Differentiated Thyroid Cancer (DTC) 84
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 83
Clinical–Pathological Features and Treatment Outcome of Patients With Hobnail Variant Papillary Thyroid Carcinoma 82
Predictors Of Vandetanib Response In The Locally Advanced Or Metastatic Medullary Thyroid Cancer: A Single Center Experience 81
A Patient with Advanced Medullary Thyroid Cancer and Progressive Symptomatic Distant Metastases: When to Start Systemic Therapy 81
Differentiated Thyroid Cancer, From Active Surveillance to Advanced Therapy: Toward a Personalized Medicine 81
Un caso di MEN2B con anomalie scheletriche multiple 79
RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency 79
Response to letter: "postoperative thyroglobulin and neck ultrasound in the risk restratification and decision to perform131i ablation" 77
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 77
Pre- And Post-Operative Circulating Tumoral Dna In Patients With Medullary Thyroid Carcinoma 76
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 75
Clinical-Pathological and Molecular Evaluation of 451 NIFTP Patients from a Single Referral Center 75
Role Of Prophylactic Central Compartment Lymph Node Dissection On The Outcome Of Patients With Papillary Thyroid Carcinoma And Synchronous Ipsilateral Cervical Lymph Node Metastases 74
Systemic treatment of advanced, metastatic, medullary thyroid carcinoma 74
Impact of energy-based devices in pediatric thyroid surgery 74
First report of benign track seeding after robot-assisted transaxillary thyroid surgery 72
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 72
null 70
Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase? 70
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 69
Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism 66
A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma 65
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 64
Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses 64
La scintigrafia con 99mTecnezio-metossi-isobutil-isonitrile è una metodica utile per caratterizzare il rischio di malignità nei noduli tiroidei a citologia indeterminata 63
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 56
MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients 56
Ultrasound features and risk stratification systems to identify medullary thyroid carcinoma 56
Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer 56
Renal complications and quality of life in postsurgical hypoparathyroidism: a case–control study 56
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 56
Obesity as a risk factor for thyroid cancer 55
Poorly differentiated and anaplastic thyroid cancer: Insights into genomics, microenvironment and new drugs 55
Management and follow-up of differentiated thyroid cancer not submitted to radioiodine treatment: a systematic review 53
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer 53
Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selpercatinib: a case report 53
Correction to: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer (Journal of Endocrinological Investigation, (2021), 44, 10, (2139-2151), 10.1007/s40618-020-01491-3) 48
Il carcinoma della tiroide 46
Higher RET gene expression levels do not represent an alternative RET activation mechanism in medullary thyroid carcinoma 40
Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib 39
Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine 39
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome 38
Effect of Pregnancy and Menopause on Micropapillary Thyroid Carcinomas During Active Surveillance 38
Thyroid carcinomas 38
Totale 9.476
Categoria #
all - tutte 36.128
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.128


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020619 0 0 0 0 0 0 0 98 113 143 233 32
2020/2021749 80 40 83 23 42 88 78 43 60 40 63 109
2021/20221.061 35 32 29 52 208 142 47 42 56 50 74 294
2022/20232.204 239 320 191 166 207 228 44 161 451 17 155 25
2023/20241.472 108 143 196 118 190 273 85 35 26 23 109 166
2024/20251.931 56 159 69 274 480 452 360 81 0 0 0 0
Totale 10.142